In addition, a dual IL-1 receptor-associated kinase-4 (IRAK4)/PIM1 inhibitor has also been found to function by blocking TLR/myeloid differentiation factor-88 (MYD88)-mediated crosstalk of NF-κB activation, inhibiting the JAK/STAT pathway and PIM1 expression, thus improving RA conditions (6). The gene discussed is PIM1; the disease is rheumatoid arthritis.